Research & Development
Mailed HPV home test kits doubled cervical cancer screening rates in study
Mailing human papillomavirus (HPV) self-collection kits for at-home use improved cervical cancer screening in under-screened, low-income women by nearly two-fold.
May 12, 2023
Mailing HPV self-sampling kits for cervical cancer screening was cost-effective in study
The study, published Wednesday in JAMA Network Open, supports mailing HPV kits as an efficient outreach strategy for increasing screening rates among eligible women.
March 22, 2023
AACC provides recommendations for detecting cervical cancer
The guidance aims to update healthcare and laboratory medicine professionals about the latest advancements in this field, and to help them select the most effective cervical cancer detection strategy for their patients, AACC said.
March 6, 2023
BioReference offering Roche Diagnostics cytology test for women at high risk for HPV
The test uses dual biomarker technology to simultaneously detect p16 and Ki-67 in women with HPV-positive results.
February 9, 2023
Fujirebio Europe secures distribution rights for Self-Screen's methylation-specific molecular assay
The test identifies women at high risk by detecting elevated methylation levels of cancer biomarkers, Fujirebio said, adding that it has been validated for both physician sample collection and sample self-collection.
October 11, 2022
Week in Review: Roche’s new MDx system, HIV world market, cervical cancer testing disparities, and more
Dear LabPulse.com member,
August 24, 2022
Combining imaging with liquid biopsy for cervical cancer
The authors -- researchers at the University of California San Diego (UCSD) and Johns Hopkins University -- noted that liquid biopsy has emerged as a promising tool that may be able to overcome some of imaging's drawbacks.
August 22, 2022
Disparities seen in cervical cancer incidence, screening
But white women have seen a greater annual increase in cervical cancer rates, particularly in adenocarcinomas, noted a team led by Dr. Alex Francoeur from the University of California, Los Angeles. The researchers found that white women have lower rates of guideline screening and vaccination compared with Black women.
August 18, 2022
Roche launches HPV self-sampling solution
The patient self-collects a sample while at a healthcare facility, following instructions provided by a healthcare worker. Then the clinically validated vaginal sample is analyzed with the Roche Cobas HPV test on one of its molecular instruments.
June 15, 2022
Agilent secures CE-IVD Mark for cervical cancer test
PD-L1 is an antibody expressed by cervical cancer tumors and is a key biomarker for predicting response to anti-PD-L1 therapies like Keytruda, according to Agilent. The company's PD-L1 IHC 22C3 pharmDx companion diagnostic identifies cervical cancer patients with a PD-L1 combined positive score of one or more, which indicates that they could benefit from treatment with Keytruda, the company said.
May 10, 2022
Seegene develops '3 Ct' assay for HPV infection
The Allplex HPV HR assay detects 14 high-risk HPV types that cause cervical cancer. The assay provides the individual Ct value of each cancer type, allowing quantitative analysis to determine the infection level. The test is expected to be launched in the first half of 2022.
April 26, 2022
Dalrada Health completes cervical cancer screening kit trial
Results from the trial were published this month in the Indian Society of Perinatology and Reproductive Biology (IJOPARB) journal. Study participants were screened for cervical cancer with cerVIA, which showed an accuracy of 91%, according to the firm. The test is patent-pending, Dalrada said.
April 24, 2022
Page 1 of 3